CRISPR, CAR-T, and NK: Current applications and future perspectives
Chimeric antigen receptor T (CAR-T) cell therapy represents a breakthrough in personalized cancer treatments. In this regard, synthetic receptors comprised of antigen recognition domains, signaling, and stimulatory domains are used to reprogram T-cells to target tum or cells and destroy them. Despit...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2024-07-01
|
| Series: | Genes and Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S235230422300404X |
| _version_ | 1797253941659959296 |
|---|---|
| author | Mohadeseh Khoshandam Hossein Soltaninejad Amir Ali Hamidieh Saman Hosseinkhani |
| author_facet | Mohadeseh Khoshandam Hossein Soltaninejad Amir Ali Hamidieh Saman Hosseinkhani |
| author_sort | Mohadeseh Khoshandam |
| collection | DOAJ |
| description | Chimeric antigen receptor T (CAR-T) cell therapy represents a breakthrough in personalized cancer treatments. In this regard, synthetic receptors comprised of antigen recognition domains, signaling, and stimulatory domains are used to reprogram T-cells to target tum or cells and destroy them. Despite the success of this approach in refractory B-cell malignancies, the optimal potency of CAR T-cell therapy for many other cancers, particularly solid tumors, has not been validated. Natural killer cells are powerful cytotoxic lymphocytes specialized in recognizing and dispensing the tumor cells in coordination with other anti-tumor immunity cells. Based on these studies, many investigations are focused on the accurate designing of CAR T-cells with clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system or other novel gene editing tools that can induce hereditary changes with or without the presence of a double-stranded break into the genome. These methodologies can be specifically focused on negative controllers of T-cells, induce modifications to a particular gene, and produce reproducible, safe, and powerful allogeneic CAR T-cells for on-demand cancer immunotherapy. The improvement of the CRISPR/Cas9 innovation offers an adaptable and proficient gene-editing capability in activating different pathways to help natural killer cells interact with novel CARs to particularly target tumor cells. Novel achievements and future challenges of combining next-generation CRISPR-Cas9 gene editing tools to optimize CAR T-cell and natural killer cell treatment for future clinical trials toward the foundation of modern cancer treatments have been assessed in this review. |
| first_indexed | 2024-04-24T21:42:04Z |
| format | Article |
| id | doaj.art-e71397b3681e4c3083e7c4de8dde7583 |
| institution | Directory Open Access Journal |
| issn | 2352-3042 |
| language | English |
| last_indexed | 2024-04-24T21:42:04Z |
| publishDate | 2024-07-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Genes and Diseases |
| spelling | doaj.art-e71397b3681e4c3083e7c4de8dde75832024-03-21T05:36:52ZengKeAi Communications Co., Ltd.Genes and Diseases2352-30422024-07-01114101121CRISPR, CAR-T, and NK: Current applications and future perspectivesMohadeseh Khoshandam0Hossein Soltaninejad1Amir Ali Hamidieh2Saman Hosseinkhani3Department of Reproductive Biology, Academic Center for Education, Culture, and Research (ACECR), Qom branch 3716986466, Iran; National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran 14965/161, IranDepartment of stem cells technology and Tissue Regeneration, Faculty of Interdisciplinary Science and Technologies, Tarbiat Modares University, Tehran 15614, Iran; Pediatric Cell Therapy and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran 1417935840, Iran; Corresponding author. Department of stem cells technology and Tissue Regeneration, Faculty of Interdisciplinary Science and Technologies, Tarbiat Modares University, Tehran 15614, Iran.Pediatric Cell Therapy and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran 1417935840, IranDepartment of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran 15614, IranChimeric antigen receptor T (CAR-T) cell therapy represents a breakthrough in personalized cancer treatments. In this regard, synthetic receptors comprised of antigen recognition domains, signaling, and stimulatory domains are used to reprogram T-cells to target tum or cells and destroy them. Despite the success of this approach in refractory B-cell malignancies, the optimal potency of CAR T-cell therapy for many other cancers, particularly solid tumors, has not been validated. Natural killer cells are powerful cytotoxic lymphocytes specialized in recognizing and dispensing the tumor cells in coordination with other anti-tumor immunity cells. Based on these studies, many investigations are focused on the accurate designing of CAR T-cells with clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system or other novel gene editing tools that can induce hereditary changes with or without the presence of a double-stranded break into the genome. These methodologies can be specifically focused on negative controllers of T-cells, induce modifications to a particular gene, and produce reproducible, safe, and powerful allogeneic CAR T-cells for on-demand cancer immunotherapy. The improvement of the CRISPR/Cas9 innovation offers an adaptable and proficient gene-editing capability in activating different pathways to help natural killer cells interact with novel CARs to particularly target tumor cells. Novel achievements and future challenges of combining next-generation CRISPR-Cas9 gene editing tools to optimize CAR T-cell and natural killer cell treatment for future clinical trials toward the foundation of modern cancer treatments have been assessed in this review.http://www.sciencedirect.com/science/article/pii/S235230422300404XCancerCAR T-cellCRISPRGene editingImmunotherapyNK cell |
| spellingShingle | Mohadeseh Khoshandam Hossein Soltaninejad Amir Ali Hamidieh Saman Hosseinkhani CRISPR, CAR-T, and NK: Current applications and future perspectives Genes and Diseases Cancer CAR T-cell CRISPR Gene editing Immunotherapy NK cell |
| title | CRISPR, CAR-T, and NK: Current applications and future perspectives |
| title_full | CRISPR, CAR-T, and NK: Current applications and future perspectives |
| title_fullStr | CRISPR, CAR-T, and NK: Current applications and future perspectives |
| title_full_unstemmed | CRISPR, CAR-T, and NK: Current applications and future perspectives |
| title_short | CRISPR, CAR-T, and NK: Current applications and future perspectives |
| title_sort | crispr car t and nk current applications and future perspectives |
| topic | Cancer CAR T-cell CRISPR Gene editing Immunotherapy NK cell |
| url | http://www.sciencedirect.com/science/article/pii/S235230422300404X |
| work_keys_str_mv | AT mohadesehkhoshandam crisprcartandnkcurrentapplicationsandfutureperspectives AT hosseinsoltaninejad crisprcartandnkcurrentapplicationsandfutureperspectives AT amiralihamidieh crisprcartandnkcurrentapplicationsandfutureperspectives AT samanhosseinkhani crisprcartandnkcurrentapplicationsandfutureperspectives |